-transparent.png){kind=logo}
Various monoclonal antibodies (mAbs) detecting certain different epitopes on myeloid cells (VIMD5, D5 D6, OKM1, Leu-M3, VIEG4, OKIa 1) have been used in combination with conventional markers (antihuman myeloid hetero-antiserum, FcIgG-receptors, C3d-receptors) to further define the phenotypic heterogeneity of myeloid leukemia. Subsequent leukemic samples from previously untreated patients with acute myeloid leukemia (AML) (51 adults, 24 children) and from nine adult patients in the acute phase of chronic myeloid leukemia (CML-BC) were studied. It was possible to demonstrate quantitative differences in the expression of antigens on the various leukemia subtypes which could be exploited for diagnosis. Furthermore our results revealed that there is a very close correlation between the different surface phenotypes and the types morphologically assessed according to FAB-criteria.
F Herrmann, and
B Komischke, and
E Odenwald, and
W D Ludwig
November 1989,
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
F Herrmann, and
B Komischke, and
E Odenwald, and
W D Ludwig
November 1981,
Cancer research,
F Herrmann, and
B Komischke, and
E Odenwald, and
W D Ludwig
July 1988,
Orvosi hetilap,
F Herrmann, and
B Komischke, and
E Odenwald, and
W D Ludwig
January 2004,
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice,
F Herrmann, and
B Komischke, and
E Odenwald, and
W D Ludwig
January 2006,
Best practice & research. Clinical haematology,
F Herrmann, and
B Komischke, and
E Odenwald, and
W D Ludwig
July 1984,
Blood,
F Herrmann, and
B Komischke, and
E Odenwald, and
W D Ludwig
April 2022,
Cancers,
F Herrmann, and
B Komischke, and
E Odenwald, and
W D Ludwig
January 1994,
Progress in clinical and biological research,
F Herrmann, and
B Komischke, and
E Odenwald, and
W D Ludwig
October 2006,
Current pharmaceutical biotechnology,
F Herrmann, and
B Komischke, and
E Odenwald, and
W D Ludwig
November 1988,
Pediatria polska,
